纽约法案可能会通过扩大340B方案的医院利润、提高费用和减少病人的选择,损害癌症护理服务。 A New York bill may harm cancer care access by expanding hospital profits in the 340B program, raising costs and reducing choices for patients.

一项拟议的纽约法案(S1913)限制对340B药物方案的监督,允许大型医院将药品价格提高四至五倍,而排除社区肿瘤学做法,从而可能使癌症护理的获得情况恶化。 A proposed New York bill, S1913, could worsen cancer care access by limiting oversight of the 340B drug program, allowing large hospitals to inflate drug prices four to five times their cost while excluding community oncology practices. 这破坏了该方案最初的目标,即援助低收入病人,每年将公共计划费用增加约8 900万美元,为医院整顿提供燃料,减少病人选择和增加共同付费,特别是在农村和服务不足的地区。 This undermines the program’s original goal of aiding low-income patients, increases costs for public plans by an estimated $89 million annually, and fuels hospital consolidation, reducing patient choices and raising copays, especially in rural and underserved areas.